[
  {
    "instruction": "What are the stages of drug development from discovery to approval?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "How long does typical drug development take and what affects timelines?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "What is the attrition rate at each phase of clinical trials?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "How do Phase 1, 2, and 3 trials differ in objectives and design?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "What determines whether a drug candidate advances to the next phase?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "How do breakthrough therapy and fast track designations affect development?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "What is the role of preclinical studies in drug development?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "How do biomarkers affect drug development strategies?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "What is adaptive trial design and when is it used?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "How do companion diagnostics affect drug development?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "What is the cost breakdown of drug development by phase?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "How do platform technologies affect drug development efficiency?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "What role do CROs play in drug development?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "How has COVID affected drug development timelines and approaches?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "What is the role of real-world evidence in drug development?",
    "input": "",
    "output": "[Drug development analysis: phase requirements, success probabilities, timeline factors, and regulatory pathway considerations.]"
  },
  {
    "instruction": "What is the current state of oncology drug development?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "How is immunotherapy transforming cancer treatment pipelines?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "What are the challenges in CNS drug development?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "How is gene therapy pipeline evolving?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "What is the state of mRNA technology beyond vaccines?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "How are cell therapies like CAR-T progressing?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "What challenges exist in Alzheimer's drug development?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "How is the obesity drug market evolving?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "What is the state of antibiotic development and market failure?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "How are rare disease drugs developed and priced?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "What is the pipeline for autoimmune disease treatments?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "How is the diabetes treatment landscape changing?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "What are the prospects for aging-related drug development?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "How is the cardiovascular drug pipeline evolving?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "What is the state of infectious disease drug development?",
    "input": "",
    "output": "[Therapeutic area analysis: pipeline status, scientific challenges, commercial dynamics, and development trends.]"
  },
  {
    "instruction": "How do FDA and EMA approval processes differ?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "What is the 505(b)(2) pathway and when is it used?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "How do accelerated approval pathways work?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "What is the biosimilar approval process?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "How do orphan drug designations affect development incentives?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "What is the REMS program and when is it required?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "How do post-marketing requirements affect drug companies?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "What is the role of advisory committees in drug approval?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "How do complete response letters affect company strategy?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "What is the FDA's approach to digital therapeutics?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "How do pediatric exclusivity requirements affect development?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "What is the regulatory pathway for combination products?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "How is China's drug regulatory framework evolving?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "What are the implications of FDA user fee negotiations?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "How do manufacturing inspections affect drug approval timelines?",
    "input": "",
    "output": "[Regulatory analysis: approval pathways, designation benefits, post-marketing requirements, and cross-jurisdiction considerations.]"
  },
  {
    "instruction": "What are the key vulnerabilities in pharmaceutical supply chains?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "How concentrated is API manufacturing geographically?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "What role does China play in pharmaceutical supply chains?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "How do drug shortages occur and propagate?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "What is the state of pharmaceutical manufacturing in the US?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "How do cold chain requirements affect vaccine distribution?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "What are the challenges in scaling up new modality manufacturing?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "How does contract manufacturing affect supply chain resilience?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "What inventory strategies do pharmaceutical companies use?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "How do quality issues cascade through pharmaceutical supply chains?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "What is the role of APIs vs. finished dosage form manufacturing?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "How do trade policies affect pharmaceutical supply chains?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "What are the supply chain considerations for cell and gene therapies?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "How do environmental regulations affect pharmaceutical manufacturing?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "What is the state of pharmaceutical serialization and track-and-trace?",
    "input": "",
    "output": "[Pharma supply chain analysis: geographic concentration, vulnerability points, shortage dynamics, and resilience strategies.]"
  },
  {
    "instruction": "How do biotech funding rounds and valuations work?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "What is the role of venture capital in biotech?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "How do licensing deals structure risk and reward?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "What triggers M&A activity in biotech?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "How do platform companies differ from pipeline companies?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "What is the IPO window dynamic in biotech?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "How do biotech valuations respond to clinical trial results?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "What is the role of partnerships in biotech development?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "How do spinouts from pharma companies work?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "What determines biotech cash runway requirements?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "How do royalty monetization deals work?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "What is the role of SPACs in biotech?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "How do biotech companies structure option deals?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "What are the economics of biotech platform licensing?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "How do activist investors affect biotech strategy?",
    "input": "",
    "output": "[Biotech business analysis: funding dynamics, deal structures, valuation drivers, and strategic partnership considerations.]"
  },
  {
    "instruction": "How do pharmaceutical patents protect market exclusivity?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "What is the Hatch-Waxman framework for generics?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "How do patent thickets and evergreening work?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "What triggers patent challenges from generic companies?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "How do biologics exclusivity periods differ from small molecules?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "What is the role of trade secrets in pharma IP strategy?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "How do pay-for-delay settlements affect competition?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "What is the IPR challenge process for pharma patents?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "How do freedom-to-operate analyses work in biotech?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "What is the state of CRISPR IP landscape?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "How do data exclusivity regulations protect originator drugs?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "What are the implications of patent term extensions?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "How do compulsory licensing provisions affect IP strategy?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "What role do patents play in mRNA technology access?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "How do international patent strategies differ by region?",
    "input": "",
    "output": "[Pharma IP analysis: exclusivity mechanisms, patent challenges, litigation dynamics, and international protection strategies.]"
  },
  {
    "instruction": "How are drug prices determined in the US vs. other countries?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "What is the role of PBMs in drug pricing?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "How do reference pricing systems work internationally?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "What are the implications of the Inflation Reduction Act for pharma?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "How do value-based contracts work for drugs?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "What role does ICER play in drug pricing debates?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "How do 340B discounts affect pharmaceutical economics?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "What is the role of specialty pharmacies in drug distribution?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "How do rebates and discounts flow through the drug channel?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "What are the economics of gene therapy pricing?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "How does outcomes-based pricing work for high-cost drugs?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "What is the role of patient assistance programs?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "How do international price comparisons affect US policy?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "What are the implications of reference product selection?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "How do biosimilar pricing dynamics differ from generics?",
    "input": "",
    "output": "[Drug pricing analysis: pricing mechanisms, channel economics, policy implications, and access considerations by market.]"
  },
  {
    "instruction": "How is AI affecting drug discovery and development?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "What is the state of protein structure prediction in drug design?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "How are organoids and organs-on-chips changing preclinical testing?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "What is the potential of targeted protein degradation?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "How is base editing different from CRISPR-Cas9?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "What are the prospects for in vivo gene editing?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "How is single-cell sequencing affecting drug development?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "What is the state of drug delivery technology innovation?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "How are digital biomarkers affecting clinical trials?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "What is the potential of epigenetic therapies?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "How is microbiome-based therapy development progressing?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "What are the prospects for radiopharmaceuticals?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "How is liquid biopsy technology affecting oncology development?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "What is the state of RNAi therapeutics after early setbacks?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  },
  {
    "instruction": "How are antibody-drug conjugates evolving?",
    "input": "",
    "output": "[Emerging technology analysis: scientific basis, development status, commercial potential, and timeline considerations.]"
  }
]